Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27081518 | 0.86 | APP (0.51) | NPC1RAB9ATDP1APPPOLB | |
| SCHEMBL30648147 | 0.86 | APP (0.51) | NPC1RAB9ATDP1APPPOLB | |
| SCHEMBL755968 | 0.84 | MAOB (0.56) | APPMAOBALDH1A1ALKBH1 | |
| SCHEMBL227169 | 0.84 | P4HTM (0.58) | RAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL733531 | 0.83 | TUBB4A (0.51) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15775775 | 0.82 | CYP4F2 (0.56) | NPC1RAB9ATDP1 | |
| SCHEMBL4548421 | 0.81 | NPC1 (0.50) | NPC1RAB9ATDP1APPPOLB | |
| SCHEMBL19801537 | 0.81 | NPC1 (0.51) | NPC1RAB9ATDP1APPPOLB | |
| SCHEMBL6873145 | 0.78 | MAOB (0.51) | NPC1RAB9ATDP1MAOB | |
| SCHEMBL16846466 | 0.77 | APP (0.66) | NPC1RAB9ATDP1APPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | NPC1 20/4885RAB9A 2584/4885TDP1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.